Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases GlobeNewswire June 01, 2025 Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly […]
LOS ANGELES, June 01, 2025 (GLOBE NEWSWIRE) — As global temperatures continue to rise and daily comfort becomes a growing concern, TORRAS is making waves with its innovative Coolify series–a wearable air conditioner engineered to deliver rapid, personal cooling through cutting-edge semiconductor technology. But beyond its impressive specs and sleek aesthetics, Coolify is also gaining
TORRAS Personal Cooling with Coolify Series: A Tech-Driven Solution for Comfort, Wellness, and Women's Health GlobeNewswire June 01, 2025 LOS ANGELES, June 01, 2025 (GLOBE NEWSWIRE) — As global temperatures continue to rise and daily comfort becomes a growing concern, TORRAS is making waves with its innovative Coolify series–a wearable air conditioner engineered to deliver
Boardwave and McKinsey & Company release analysis that identifies five priority interventions to unlock growth opportunities to scale and retain global software companies Europe's software sector has a 'once-in-a-generation' opportunity to lead the next wave of global technology innovation – if it can overcome a persistent scale-up barrier. https://mma.prnewswire.com/media/2700695/5347621/Boardwave_Logo.jpg The joint report by Boardwave, the
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / WHY: New York, N.Y., June 1, 2025. Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) during the period from October 11,
(NASDAQ:KURA),(TSE:4151),(TSE:4151.T), – New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potential first approval of a menin inhibitor for the treatment of adult patients with relapsed or refractory AML with an
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML GlobeNewswire June 01, 2025 – New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target
NEW YORK, NY / ACCESS Newswire / June 1, 2025 / If you suffered a loss on your Bitfarms Ltd. (NASDAQ:BITF) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bitfarms-ltd-lawsuit-submission-form?prid=151197&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
NEW YORK, NY / ACCESS Newswire / June 1, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151196&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / June 1, 2025 / If you suffered a loss on your BigBear.ai Holdings, Inc. (NYSE:BBAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bigbear-ai-holdings-inc-lawsuit-submission-form?prid=151195&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or